Back to top
more

AtriCure (ATRC)

(Delayed Data from NSDQ)

$36.35 USD

36.35
851,782

+1.94 (5.64%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $36.39 +0.04 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AtriCure (ATRC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

AtriCure (ATRC) delivered earnings and revenue surprises of +86.67% and +4.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Abbott (ABT) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Abbott (ABT) delivered earnings and revenue surprises of +0.80% and +0.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Amneal Pharmaceuticals (AMRX) and AtriCure (ATRC) have performed compared to their sector so far this year.

Zacks Equity Research

Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?

by Zacks Equity Research

Here is how Astellas Pharma Inc. (ALPMY) and AtriCure (ATRC) have performed compared to their sector so far this year.

Zacks Equity Research

Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Astellas Pharma Inc. (ALPMY) and AtriCure (ATRC) have performed compared to their sector so far this year.

Zacks Equity Research

Does AtriCure (ATRC) Have the Potential to Rally 54.7% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 54.7% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

AtriCure (ATRC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

AtriCure (ATRC) delivered earnings and revenue surprises of 44% and 0.16%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

LeMaitre (LMAT) Soars 7.7%: Is Further Upside Left in the Stock?

by Zacks Equity Research

LeMaitre (LMAT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Neogen (NEOG) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Neogen (NEOG) delivered earnings and revenue surprises of -23.08% and 0.92%, respectively, for the quarter ended February 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how AnaptysBio, Inc. (ANAB) and AtriCure (ATRC) have performed compared to their sector so far this year.

Zacks Equity Research

Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

AtriCure (ATRC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

AtriCure (ATRC) delivered earnings and revenue surprises of 46.67% and 0.01%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exploring Analyst Estimates for AtriCure (ATRC) Q4 Earnings, Beyond Revenue and EPS

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for AtriCure (ATRC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.

Zacks Equity Research

Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline

by Zacks Equity Research

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Brainsway (BWAY) Moves 8.0% Higher: Will This Strength Last?

by Zacks Equity Research

Brainsway (BWAY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

AtriCure (ATRC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

AtriCure (ATRC) delivered earnings and revenue surprises of 15% and 2.95%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AtriCure's Stock Rises After Launch of cryoSPHERE MAX Device

by Zacks Equity Research

ATRC's cryoSPHERE MAX probe cuts freeze times by 50%, advancing Cryo Nerve Block therapy to improve post-op pain relief and reduce opioid dependency risks.

Zacks Equity Research

AtriCure Gets CE Mark for EnCompass Clamp, Expands in Europe

by Zacks Equity Research

ATRC's EnCompass Clamp receives a CE Mark, enabling European surgeons to access faster, simpler heart ablation in cardiac surgeries with advanced radiofrequency technology.

Zacks Equity Research

AtriCure's Shares Likely to Benefit From New AtriClip Device Sales

by Zacks Equity Research

ATRC announces the treatment of the first patient using the AtriClip FLEX-Mini device.

Zacks Equity Research

AtriCure's (ATRC) AtriClip Receives Expanded CE-Mark Indication

by Zacks Equity Research

AtriCure (ATRC) announces the receipt of an expanded CE-Mark indication for its AtriClip devices for reducing strokes in patients with Afib.